Business ❯ Healthcare

Biopharmaceuticals

Drug Development Clinical Trials Oncology Plasma Products Product Development Research and Development Company Operations Therapeutics Manufacturing Dermatology Investor Relations Product Portfolio HIV Treatments Biocon Pulmonary Hypertension Innovative Treatments Market Competition Plasma Industry Medical Devices Company Performance Market Capitalization Genetic Diseases RNA Therapeutics Plasma-derived Medicines COVID-19 Treatments Clinical Products Immunology Rare Diseases Allergy Treatments Biosimilars Market Growth Industry Performance Biocon Ltd Product Performance Impact BioMedical Inc. Hepatitis C Treatments Market Trends Pharmaceutical Companies Cancer Therapies Company Profiles Respiratory Treatments Pulmonary Delivery Technology Gene Therapy Contract Research Organizations Company Structure Gilead Sciences Cardiovascular Medicine Immunotherapy FDA Approval Corporate Partnerships

Veeva Tops Q2 Forecast and Raises Guidance as Vault CRM Momentum Drives Rally

The quarter reflects robust subscription growth and high company‑defined margins, with Veeva presenting Falcon AI as the next growth lever.

AbbVie to Buy Apogee for About $10.9 Billion to Add Clinical-Stage IL-13 Drug

Parabilis Prices Upsized IPO at $20, Raising $670 Million

Ivonescimab Shows Two‑Year Survival Gain in China Phase 3 Trial

Liminatus Announces Merger to Acquire InnocsAI and Expand CAR‑T Portfolio

Gilead Lifts 2026 Sales Outlook, Warns of Loss on $11.5 Billion Deal Charge

AbbVie Tops Q1 and Raises 2026 Outlook as Skyrizi and Rinvoq Offset Humira Decline

Simulations Plus Beats Q2, Lowers FY2026 Profit Outlook

ADMA Biologics Denies Short-Seller Report as Shares Rebound and Law Firms Launch Probes

Biofrontera Reports Record 2025 Revenue of $41.7 Million and Best-Ever Q4 at $17.1 Million

Servier to Acquire Day One Biopharma in $2.5 Billion All-Cash Deal at $21.50 a Share

Cantor Raises Innoviva Target to $32 After Q4 Beat on China XacDuro Builds

AstraZeneca Shifts U.S. Listing to NYSE as Nasdaq ADSs End Jan. 30

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

MPM BioImpact Exits MBX, MoonLake, Crinetics in Q3, SEC Filing Shows

CorMedix Shares Jump After Q3 Beat as Company Lifts 2025 Outlook

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Analyst Warns Eli Lilly’s GLP-1 Lead Is Fading as CFRA Lifts Rating to Buy

Liquidia Reports 900+ Yutrepia Prescriptions in 11 Weeks, Targets Profitability Within 3–4 Quarters